Desvenlafaxine for the treatment of major depressive disorder

Bibliography

• Rush AJ, Kilner J, Fava M, et al. Clinically relevant findings from STAR*D. Psychiatr Ann 2008;38:188-93
   Web of Science ®Google Scholar
• The global burden of disease. 2004 update. World Health Organization. 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html [Last accessed 9 November 2012]
   Google Scholar
• Depression. World Health Organization. 2012. Available from: http://www.who.int/mental_health/management/depression/definition/en/print.html [Last accessed 11 June 2008]
   Google Scholar
• Patten SB, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord 2009;117(Suppl 1):S5-14
   PubMed Web of Science ®Google Scholar
• Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;109(420):21-7
   Google Scholar
• Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association, 2010. Available from: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx [Last accessed 1 February 2012]
   Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
   PubMed Web of Science ®Google Scholar
• Gill JM, Klinkman MS, Chen YX. Antidepressant medication use for primary care patients with and without medical comorbidities: a national electronic health record (EHR) network study. J Am Board Fam Med 2010;23:499-508
   PubMed Web of Science ®Google Scholar
• Serna MC, Cruz I, Real J, et al. Duration and adherence of antidepressant treatment (2003 – 2007) based on prescription database. Eur Psychiatry 2010;25:206-13
   PubMed Web of Science ®Google Scholar
• Depression in adults. The treatment and management of depression in adults. National Institute for Health and Clinical Excellence. 2009. Available from: http://www.nice.org.uk/nicemedia/live/12329/45888/45888.pdf [Last accessed 29 July 2013]
   Google Scholar
• Milea D, Guelfucci F, Bent-Ennakhil N, et al. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther 2010;32:2057-72
   PubMed Web of Science ®Google Scholar
• Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry 2000;61(Suppl 2):10-12
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010;40:41-50
   PubMed Web of Science ®Google Scholar
• Romera I, Perez V, Menchon JM, et al. Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study. Eur Psychiatry 2010;25:58-65
   PubMed Web of Science ®Google Scholar
• D’Avanzato C, Martinez J, Attiullah N, et al. Anxiety symptoms among remitted depressed outpatients: prevalence and association with quality of life and psychosocial functioning. J Affect Disord 2013;151:401-4
   PubMed Web of Science ®Google Scholar
• Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010;122:184-91
   PubMed Web of Science ®Google Scholar
• Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346-53
   PubMed Web of Science ®Google Scholar
• Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004;38:249-57
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 1996;11:137-45
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000;61:851-7
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004;65:44-9
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-66
   PubMed Web of Science ®Google Scholar
• Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Flockhart D. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006;13:35-64
   Google Scholar
• Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management. J Clin Psychiatry 2013;74:407-14
   PubMed Web of Science ®Google Scholar
• Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med 2007;32:127-34
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
   PubMed Web of Science ®Google Scholar
• Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54
   PubMed Web of Science ®Google Scholar
• Saraceni MM, Venci JV, Gandhi MA. Levomilnacipran (Fetzima): a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. J Pharm Pract 2013. [ Epub ahead a print]
   PubMedGoogle Scholar
• Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
   PubMed Web of Science ®Google Scholar
• Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry 2013;203:179-87
   PubMed Web of Science ®Google Scholar
• Brintellix [package insert]. Lundbeck, Deerfield, IL; 2013
   Google Scholar
• Fetzima [package insert]. Forest Pharmaceuticals, Inc, St. Louis, MO; 2013
   Google Scholar
• Valdoxan summary of product characteristics. EMedicines, London, United Kingdom; 2013
   Google Scholar
• Pristiq [package insert]. Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, Philadelphia, PA; 2013
   Google Scholar
• Pristiq [product monograph]. Pfizer Canada Inc, Kirkland, Quebec, Canada; 2013
   Google Scholar
• Nichols AI, Behrle JA, Richards LS, et al. The absolute bioavailability of desvenlafaxine in healthy subjects. J Bioequiv Availab 2012;4:018-23
   Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Debonnel G, Saint-Andre E, Hebert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007;10:51-61
   PubMed Web of Science ®Google Scholar
• Nichols AI, Tourian KA, Tse SY, et al. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010;6:1565-74
   PubMed Web of Science ®Google Scholar
• DeMaio W, Kane CP, Nichols AI, et al. Metabolism studies of desvenlafaxine. J Bioequiv Availab 2011;3:151-60
   Google Scholar
• Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502
   PubMed Web of Science ®Google Scholar
• Effexor XR [package insert]. Wyeth Pharmaceuticals, Inc, Philadelphia, PA; 2012
   Google Scholar
• Nichols AI, Behrle JA, Parks V, et al. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor. J Bioequiv Availab 2013;5:22-30
   Google Scholar
• Nichols AI, Richards LS, Behrle JA, et al. Effects of age and sex on the pharmacokinetics, safety, and tolerability of oral desvenlafaxine in healthy adults. J Bioequiv Availab 2013;5:88-94
   Google Scholar
• Nichols AI, Richards LS, Behrle JA, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Ther 2011;49:3-13
   PubMed Web of Science ®Google Scholar
• Baird-Bellaire S, Behrle JA, Parker VD, et al. An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine. Clin Ther 2013;35:782-94
   PubMed Web of Science ®Google Scholar
• Preskorn S, Patroneva A, Silman H, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43
   PubMed Web of Science ®Google Scholar
• Nichols AI, Focht K, Jiang Q, et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011;31:155-67
   PubMed Web of Science ®Google Scholar
• Lobello KW, Preskorn SH, Guico-Pabia CJ, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010;71:1482-7
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. Drug Interaction Studies–Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Administration. 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf [Last accessed 20 May 2013]
   Google Scholar
• Patroneva A, Connolly SM, Fatato P, et al. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008;36:2484-91
   PubMed Web of Science ®Google Scholar
• Nichols AI, Fatato P, Shenouda M, et al. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 2009;49:219-28
   PubMed Web of Science ®Google Scholar
• Nichols AI, Abell M, Chen Y, et al. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults. Int Clin Psychopharmacol 2013;28:99-105
   PubMed Web of Science ®Google Scholar
• Nichols A, Liang Y, Matschke K, et al. An evaluation of the potential of cytochrome P450 3A4-mediated drug-drug interactions with desvenlafaxine use. J Bioequiv Availab 2013;5:53-9
   Google Scholar
• Nichols AI, Lubaczewski S, Liang Y, et al. An open-label evaluation of the effect of coadministering desvenlafaxine 100 mg on the pharmacokinetics of aripiprazole in healthy subjects. J Bioequiv Availab 2013;5:253-9
   Google Scholar
• Nichols AI, Lubaczewski S, Liang Y, et al. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when co-administered in healthy postmenopausal female subjects. J Clin Pharm Ther 2014; In Press
   Web of Science ®Google Scholar
• Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull 2009;42:47-63
   PubMed Web of Science ®Google Scholar
• Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, et al. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 2011;32:233-44
   PubMed Web of Science ®Google Scholar
• Bachmeier C, Levin GM, Beaulieu-Abdelahad D, et al. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. J Pharm Sci 2013;102:3838-43
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31 Pt 1:1405-23
   PubMed Web of Science ®Google Scholar
• Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013;19:5-14
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011;31:569-76
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2013;74:1010-17
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry 2013;13:94
   PubMed Web of Science ®Google Scholar
• Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2923-8
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Clayton A, Tourian KA, Focht K, et al. Desvenlafaxine 50- and 100-mg/d vs placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry 2014; In Press
   Google Scholar
• Ferguson J, Tourian K, Manley A, et al. An evaluation of the efficacy, safety, and tolerability of desvenlafaxine in the long-term treatment of elderly outpatients with major depressive disorder. Prim Psychiatry 2010;17:66-73
   Google Scholar
• Tourian KA, Pitrosky B, Padmanabhan SK, et al. A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorder. Prim Care Companion CNS Disord 2011;13:e1-e10
   PubMedGoogle Scholar
• Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 2012;17:121-30
   PubMed Web of Science ®Google Scholar
• Tourian K, Wang Y, Ii Y. A. 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Int Clin Psychopharmacol 2013;28:206-13
   PubMed Web of Science ®Google Scholar
• Rickels K, Montgomery SA, Tourian KA, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010;30:18-24
   PubMed Web of Science ®Google Scholar
• Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry 2013;74:158-66
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Fava M, Jiang Q, et al. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Psychopharmacol Bull 2009;42:21-35
   PubMedGoogle Scholar
• Tourian KA, Jiang Q, Ninan PT. Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectr 2010;15:187-93
   PubMed Web of Science ®Google Scholar
• Soares CN, Endicott J, Boucher M, et al. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sheehan DV. Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, editors. Handbook of psychiatric measures. American Psychiatric Association, Washington, DC; 2000. p. 113-15
   Google Scholar
• World Health Organization. Wellbeing measures in primary health care/the depcare project. World Health Organization Regional Office for Europe. 1998. Available from: http://www.euro.who.int/__data/assets/pdf_file/0016/130750/E60246.pdf [Last accessed 20 March 2012]
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
   PubMed Web of Science ®Google Scholar
• Soares CN, Kornstein SG, Thase ME, et al. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry 2009;70:1365-71
   PubMed Web of Science ®Google Scholar
• Lam RW, Endicott J, Hsu MA, et al. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int Clin Psychopharmacol 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nicholson S, Sweeney M, Whiteley J, et al. Is there a business case for reducing employees’ antidepressant prescription drug cost sharing? J Health Productivity 2012;6:14-22
   Google Scholar
• Endicott J, Lam R, Hsu M-A, et al. Improvements in quality of life in employed adults treated for major depressive disorder with desvenlafaxine 50 mg/d vs placebo [poster]. Presented at: United States Psychiatric and Mental Health Congress; 8-11 November 2012; San Diego, CA
   Google Scholar
• Reddy S, Focht K, Musgnung J, et al. The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder [poster]. Presented at: annual Meeting of the College of Psychiatric and Neurologic Pharmacists; 1-4 May 2011; Phoenix, AZ
   Google Scholar
• Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2010;71:1088-96
   PubMed Web of Science ®Google Scholar
• Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause 2010;17:700-11
   PubMed Web of Science ®Google Scholar
• Soares CN, Thase ME, Clayton A, et al. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs 2011;25:227-38
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Clayton AH, Soares CN, et al. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol 2010;30:294-9
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Culpepper L, Fayyad RS, et al. Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of 6 randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2013;28:312-21
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Guico-Pabia CJ, Fayyad RS. The effect of desvenlafaxine 50 mg/d on a subpopulation of anxious/depressed patients: a pooled analysis of 7 randomized, placebo-controlled studies [poster]. Presented at: Annual New Clinical Drug Evaluation Unit Meeting; 29-May 1 June 2012; Phoenix, AZ
   Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Fava M, Padmanabhan SK, et al. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol 2009;24:296-305
   PubMed Web of Science ®Google Scholar
• Khan A, Musgnung J, Ramey T, et al. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatr Treat 2007;13:447-57
   Google Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
   PubMed Web of Science ®Google Scholar
• Clayton AH, Reddy S, Focht K, et al. An evaluation of sexual functioning in employed outpatients with major depressive disorder treated with desvenlafaxine 50 mg or placebo. J Sex Med 2013;10:768-76
   PubMed Web of Science ®Google Scholar
• Tourian KA, Leurent C, Graepel J, et al. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010;12:CC
   Google Scholar
• McIntyre RS, Fayyad RS, Guico-Pabia CJ, et al. Weight change in depressed patients treated with desvenlafaxine 50 and 100 mg/d vs placebo [poster]. Presented at: United States Psychiatric and Mental Health Congress; 8 - 11 November 2012; San Diego, CA
   Google Scholar
• Laughren TP. Overview for December 13 meeting of psychopharmacologic drugs advisory committee (PDAC) [memorandum]. Food and Drug Administration. 2006. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf [Last accessed 19 April 2012]
   Google Scholar
• Tourian KA, Padmanabhan K, Groark J, et al. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. J Clin Psychopharmacol 2010;30:411-16
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
   PubMedGoogle Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74
   PubMed Web of Science ®Google Scholar
• Coleman KA, Xavier VY, Palmer TL, et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr 2012;17:131-41
   PubMed Web of Science ®Google Scholar
• Cymbalta [package insert]. Eli Lilly and Company, Indianapolis, IN; 2011
   Google Scholar
• Schwartz TL. Metabolites: novel therapeutics or "me-too" drugs? Using desvenlafaxine as an example. CNS Spectr 2012;17:103-6
   PubMed Web of Science ®Google Scholar
• Eisenberg D, Isenberg KE, Gu T, et al. Treatment and healthcare utilization among commercially insured patients with major depressive disorder. Am J Pharm Benef 2013;5:e55-65
   Google Scholar
• Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res 2014; In press
   PubMed Web of Science ®Google Scholar
• Archer DF, Dupont CM, Constantine GD, et al. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238
   PubMed Web of Science ®Google Scholar
• Archer DF, Seidman L, Constantine GD, et al. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172. e10
   PubMed Web of Science ®Google Scholar
• Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
   PubMed Web of Science ®Google Scholar
• Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15:12-20
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Constantine G, Hwang E, et al. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20:28-37
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007;68:1663-72
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 2008;23:188-97
   PubMed Web of Science ®Google Scholar
• Feiger AD, Tourian KA, Rosas GR, et al. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectr 2009;14:41-50
   PubMed Web of Science ®Google Scholar
• Guico-Pabia CJ, Fayyad RS, Soares CN. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int Clin Psychopharmacol 2012;27:1-7
   PubMed Web of Science ®Google Scholar
• Soares CN, Fayyad RS, Guico-Pabia CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol 2014;34:57-65
   PubMed Web of Science ®Google Scholar